Dendrobium Officinale Polysaccharide Attenuates Insulin Resistance and Abnormal Lipid Metabolism in Obese Mice

Jian Qu, Shengyu Tan, Xinyan Xie, Weniqiang Wu, Haihong Zhu, Hang Li, Xiaobo Liao, Jiaojiao Wang, Zhi-Ang Zhou, Song Huang, and Qiong Lu

Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China; Department of Geriatrics, The Second Xiangya Hospital of Central South University, Changsha, China; Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China; Department of Cardiovascular Surgery, The Second Xiangya Hospital, Central South University, Changsha, China

Objectives: Dendrobium officinale polysaccharide (DOP) is the main active ingredient in a valuable traditional Chinese medicine, which exerts several pharmacological activities including hepatoprotection and hypoglycemic effects. However, the effects of DOP on obesity-associated insulin resistance (IR) and lipid metabolism remain unknown. This study aimed to investigate the role of DOP in IR and abnormal lipid metabolism in obese mice.

Methods: IR models were established using 3T3-L1 adipocytes, C2C12 myocytes, and primary cultured hepatocytes exposed to palmitate acid. After treatment with DOP, insulin-stimulated glucose uptake, glucose release, and AKT phosphorylation was detected. Fasting blood glucose, fasting serum insulin, the glucose tolerance test (GTT), and the insulin tolerance test (ITT) were measured to evaluate IR of obese mice. Lipid analysis was conducted to evaluate the effects of DOP on lipid metabolism in obese mice.

Results: In vitro, DOP treatment ameliorated palmitic acid-induced IR in adipocytes, myocytes, and hepatocytes. DOP regulated cellular insulin sensitivity via the peroxisome proliferator-activated receptor-γ (PPAR-γ). Furthermore, administration of DOP significantly reduced the IR and visceral adipose tissue (VAT) inflammation of diet-induced obese (DIO) and the genetically-induced obesity (ob/ob) mouse models. In addition, DOP treatment attenuated the high-fat diet (HFD)-induced liver lipid accumulation by reducing liver triglycerides (TG), plasma free fatty acid (FFA), serum cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) levels, while increasing HDL-C levels.

Conclusion: DOP could improve obesity-associated IR and abnormal lipid metabolism through its activities on PPAR-γ, and may serve as a potential therapeutic agent for obesity-associated insulin resistance and lipid metabolism disorder.

Keywords: abnormal lipid metabolism, Dendrobium officinale polysaccharide, insulin resistance, obesity, peroxisome proliferator-activated receptor-γ.

Abbreviations: DIO, Diet-induced obese; DOP, Dendrobium officinale polysaccharide; FFA, Free fatty acid; GTT, Glucose tolerance test; HDL-C, High-density lipoprotein cholesterol; HFD, High-fat diet; HOMA-IR, Homeostasis model assessment of insulin resistance; IR, Insulin resistance; ITT, Insulin tolerance test; LDL-C, Low-density lipoprotein cholesterol; PPAR-γ, Peroxisome proliferator-activated receptor-γ; TC, Serum cholesterol; TG, Triglycerides; VAT, Visceral adipose tissue.
INTRODUCTION

With rapid economic growth, obesity is becoming an increasing health concern worldwide. Understandably, obesity was defined as a disease by the Obesity Society (TOS) in 2008 (Belkina and Denis, 2016; Jastrzeboff et al., 2019). Obesity is characterized by increased circulating fatty acid levels resulting from excessive lipolysis and absorption of basal adipose tissue, which in turn promote the development of ectopic lipid deposition and insulin resistance (IR) (Crowe et al., 2009). Consistently, studies have shown that obesity is a risk factor for metabolic syndrome, which includes IR and dyslipidemia, impaired fasting blood glucose, and hyperinsulinemia (Laaksonen et al., 2002; Meigs et al., 2006). In addition, obesity increases the risk and mortality of many diseases. Council of the Obesity (2008), González-Domínguez et al. (2020), especially type 2 diabetes, cardiovascular disease, hypertension, and dyslipidemia (De Lorenzo et al., 2019).

IR refers to the reduction of insulin sensitivity and response to insulin target organs and tissues (liver, adipose tissue, skeletal muscle) due to varied reasons (Samuel and Shulman, 2012). This leads to a decrease in glucose uptake and utilization. Therefore, the body will compensatively secrete excess insulin to maintain the stability of blood sugar, leading to hyperinsulinemia, which in turn leads to dyslipidemia. Dyslipidemia manifests as increased total cholesterol (TC), triglycerides (TG), and free fatty acids (FFA), normal or slightly increased low-density lipoprotein cholesterol (LDL-C), and decreased high-density lipoprotein cholesterol (HDL-C) (Klop et al., 2013). Moreover, the symptoms of IR are impaired glucose absorption in muscles and increased gluconeogenesis in the liver during fasting and postprandial conditions, leading to hyperglycemia (Moller and Kaufman, 2005). Insulin-sensitive tissues (adipose tissue, heart, and liver) are significantly affected by obesity at biomolecular and functional levels (Barazzoni et al., 2018). Excessive fat accumulation can change the function of adipose organs and leads to obesity-related diseases (Ling and Ronn, 2019). In addition, a close relationship between the mechanisms implicated in lipid metabolic disorders and IR has also been reported (Savage et al., 2007). Further, obesity and IR are closely related to inflammation of metabolic tissues, including the liver, muscle, and adipose tissue (Winer et al., 2016; Wu and Ballantyne, 2017; Ghoprade et al., 2018). Excessive fat accumulation and abnormal lipid metabolism caused by obesity induce the transformation of macrophages from the anti-inflammatory M2 polarized state to the pro-inflammatory M1 polarized state, leading to VAT inflammation, thus promoting the development of obesity-related IR (Xu et al., 2003; Lumeng et al., 2007; Kotja et al., 2020). At the same time, IR further aggravates lipid metabolism disorders, leading to a series of metabolic disorders such as diabetes and cardiovascular diseases. The specific manifestations of visceral adipose tissue (VAT) inflammation are increased levels of pro-inflammatory cytokines such as tumor necrosis factor (TNF-α) and interleukin (IL)-6 Hotamisligil et al. (1993), Kern et al. (2001), and decreased levels of anti-inflammatory cytokines IL-10 and IL-4 in obesity-related IR patients (Esposito et al., 2003). Therefore, the prevention or treatment of IR and lipid metabolism disorders may be an effective way to inhibit obesity-related diseases.

_Dendrobium officinale Kimura et Migo_ is a valuable traditional Chinese medicine that has been used to treat diabetes, obesity, rheumatoid arthritis, and many other diseases. It has been reported that _Dendrobium officinale Kimura et Migo_ can inhibit the effects of oxidative stress and pro-inflammatory cytokines (Teixeira da Silva et al., 2015). Oxidative stress and inflammation may also lead to obesity-related IR (Xu et al., 2003; Gorton Cappellari et al., 2016). _Dendrobium officinale_ polysaccharide (DOP) is the main active component of _Dendrobium officinale Kimura et Migo_, which exerts pharmacological activities including antioxidation, lowering blood lipids and blood sugar levels, and hepatoprotection (Huang et al., 2016). In type 2 diabetic rats, DOP treatment reduced hepatic lipid metabolism disorders and alleviated symptoms of hepatic lipid accumulation (Yang et al., 2020). These studies indicated that DOP is expected to be a novel therapeutic agent for obesity-related diseases including IR and abnormal lipid metabolism. However, to date, there are almost no available mechanistic studies investigating mechanistic studies on the effects of DOP in IR and abnormal lipid metabolism. Meanwhile, the mechanism of DOP in obesity-related IR and abnormal lipid metabolism is still unclear.

The purpose of this study was to explore the effects and mechanisms of action of DOP on obesity-related IR and lipid metabolism disorders. First, at the cellular level, we measured glucose uptake, glucose output, and Akt phosphorylation in insulin-stimulated hepatocytes, muscle cells, and adipocytes, respectively. The results showed that DOP treatment could improve IR-induced obesity. Subsequently, we conducted a mechanism study and found that DOP mainly acted on peroxisome proliferator-activated receptor-γ (PPAR-γ) signaling to regulate insulin sensitivity in diet-induced obesity (DIO) mice. We evaluated how DOP could improve IR in DIO mice by assessing fasting blood glucose and fasting serum insulin levels, the glucose tolerance test (GTT), the insulin tolerance test (ITT), and the inflammation related indicators of VAT. Furthermore, lipid analysis showed that DOP attenuated the abnormal lipid metabolism in DIO mice. We also validated the therapeutic effects of DOP in the genetically-induced obesity mice (ob/ob mice) model. Overall, we expect that our study can provide a basis for the clinical application of DOP in obesity-related IR and lipid metabolism disorders.

MATERIALS AND METHODS

Animal Models

To establish a diet-induced obese (DIO) mice model, two-month-old male C57BL6 mice were fed a high-fat diet (HFD, 60% fat, 20% protein, and 20% carbohydrate) for 3 months. Ob/ob mice are a classical experimental model of obesity-induced IR as evidenced by a plethora of studies. Ob/ob mice harbor a recessive mutation in leptin and are characterized by hyperphagia, obesity, hyperinsulinemia, insulin-resistance (IR), and hyperglycemia; thus, they are commonly used as a model for
studies of diabetes and obesity. Ob/ob mice were purchased from Hunan SJA Laboratory Animal Co., Ltd. (license number: SCXK 2019-0004). All animals were housed under 12-h light/dark cycles and were provided unrestricted access to food and water unless otherwise specified.

For in vivo DOP treatment, after 3 months of a HFD, the DIO mice were divided into two groups, the control group and the experimental group, the control group received normal saline (NS) orally, and the experimental group was administrated DOP (150 mg/kg) orally, once daily for 3 months. The DOP involved in this study was prepared by the laboratory of Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine (Liang et al., 2018; Liang et al., 2019). The proportion of total polysaccharides in the DOP was 93.80%. Moreover, the FT-IR spectrogram showed that DOP has an intense and broad absorption peak around 3414 cm⁻¹, a weak absorption peak at 2924 cm⁻¹ and 1324 cm⁻¹, and an asymmetrical extension at 1175 cm⁻¹ (Figure 1A). And GC chromatogram of monosaccharide composition showed that DOP had the characteristic absorption profile of polysaccharides. DOP is composed of mannose, glucose, and arabinose with a molar ratio of 5.55:1:0.12 (Figure 1B). The average molecular weight of DOP was 393.8 kDa by HPLC profiles of molecular weight measurement (Figure 1C). The formulation was identical to the DOP prepared by Hua (Hua et al., 2004).

All protocols pertaining to animal care and experiments were reviewed and approved by the Institutional Animal Care and Use Committee of the Laboratory Animal Research Center at Xiangya Medical School of Central South University, China.

Cell Culture and Treatment
Primary hepatocytes, C2C12 myoblasts, and 3T3-L1 preadipocytes were cultured in a humidified incubator at 37°C and supplemented with 5% CO2. Standard protocols were utilized to induce differentiation of these cells. To establish IR models, primary hepatocytes, C2C12, myoblasts, and 3T3-L1 preadipocytes were treated with 0.5 mmol/L palmitate acid (PA; Sigma) for 24 h. Glucose levels in the medium were measured to determine whether the IR model was successful. For in vitro DOP treatment, 200 μg/ml DOP was added to the culture medium for 48 h.

Cell Viability
The Cell Counting Kit-8 (CCK-8) was used to assess the viability of 3T3-L1 adipocytes after DOP treatment, as per the manufacturer’s protocol. Absorbance was measured at 450 nm via a microplate reader (Thermo Electron Corp).
Glucose Uptake and Glucose Output Assay

The glucose uptake and glucose output assays were performed as described previously (Su et al., 2019). The medium glucose levels were measured by a Glucose Assay Kit (Abcam, ab65333) according to the manufacturer’s instructions.

### Western Blot and qRT-PCR Analysis

Western blotting analysis was conducted as previously described (Li et al., 2009). Primary antibodies p-AKT (CST9272s; Dilution 1:1,000) and AKT (CST9272s; Dilution 1:1,000) were purchased from Cell Signaling Technology, and PPAR-γ (ab209350, Dilution 1:1,000) was purchased from Abcam. All primary antibodies were incubated at 4°C overnight, the secondary antibodies were diluted to 1:5,000, and specific proteins were visualized by ECL Plus. For qRT-PCR analysis, the total RNA from cultured cells were isolated by TRIzol (Thermo Fisher Scientific). The list of primers used for real-time PCR analysis are described in Table 1.

Blood Glucose, Serum Insulin, Insulin Tolerance Test, Glucose Tolerance Test, and HOMA-IR Index

The measurement of blood glucose levels and serum insulin, and the performance of the ITT and GTT, have been reported previously (Ying et al., 2017; Xiao et al., 2020). The following formula was used to calculate the homeostasis model assessment of IR (HOMA-IR) index: [fasting blood glucose levels (mmol/L)] × [fasting serum insulin levels (μU/ml)]/22.5 (Su et al., 2019).

Lipid Analysis

Approximately, 0.1 g liver was homogenized in phosphate-buffered saline (PBS) solution (1:9 ratio). The mixture was centrifuged at 2,500 rpm for 10 min at 4°C after which the supernatant was collected. The cytoplasm of L02 cells was collected with 2% Triton X-100. Hepatic and hepatocellular TG were quantified using chemical reagent kits from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). In addition, serum lipids including TC, TG, LDL-C, and HDL-C levels were determined using kits from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Plasma-free fatty acid (FFA) levels were measured enzymatically using a kit from WAKO Chemicals. Absorbance values of all samples were measured using a spectrophotometric system.

### Hematoxylin and Eosin Staining and Oil Red O Staining

Livers samples (4–5 micron in thickness) were placed in cassettes and submerged in 10% formalin solution overnight. Samples were processed in a dehydrating ethanol gradient, followed by xylene incubation and paraffin embedding. Serial 8-μm sections were used for hematoxylin and eosin (H&E) staining and Oil Red O staining.

### Quantification and Statistical Analysis

All data are presented as mean ± SD. For comparisons between two groups, a two-tailed Student’s t-test was used. Comparisons between multiple groups were performed using ANOVA followed by Bonferroni’s post-hoc correction. A p-value < 0.05 was considered statistically significant.

### RESULTS

#### DOP Ameliorated Cellular Insulin Resistance In Vitro

The cytotoxicity of DOP was assessed by the CCK-8 assay, which revealed DOP did not affect cell viability at concentrations of 100, 200, and 400 μg/ml (Figure 2A). To explore whether DOP participated in the regulation of insulin sensitivity, we treated PA-induced adipocytes, myocytes, and hepatocytes with DOP. As expected, DOP treatment significantly promoted the insulin-stimulated glucose uptake of 3T3-L1 adipocytes and C2C12 myocytes (Figures 2B,C), while the glucose output of primary cultured hepatocytes decreased (Figure 2D). In addition, the insulin-stimulated AKT phosphorylation of 3T3-L1 adipocytes, C2C12 myocytes, and primary cultured hepatocytes was increased following DOP treatment (Figure 2E). Taken together, these results suggested that DOP ameliorated cellular IR of adipocytes, myocytes, and hepatocytes in vitro.

#### DOP Regulated Cellular Insulin Sensitivity by Activating PPAR-γ

Pharmacological activation of PPAR-γ has emerged as an effective method for treating diabetes. We found that the transcript levels of PPAR-γ mRNA in 3T3-L1 adipocytes, C2C12 myocytes, and primary cultured hepatocytes treated with DOP were elevated (Figures 3A–C). Western blotting analysis further confirmed that DOP could promote the protein expression levels of PPAR-γ (Figure 3D). These
observations suggested that DOP increased the expression of PPAR-γ. To validate whether DOP regulated cellular insulin sensitivity through the activation of PPAR-γ, we treated PA-induced adipocytes and myocytes with GW9662, a PPAR-γ antagonist. GW9662 is a potent and selective PPAR-γ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPAR-δ, respectively. The chemical structure is shown in Figure 1D. The effects of DOP on 3T3-L1 adipocytes and C2C12 myocytes were abrogated by GW9662, which indicated that DOP failed to improve the insulin sensitivity if PPAR-γ was inhibited (Figures 3E,F). Taken together, these results indicated that DOP regulated cellular insulin sensitivity by activating PPAR-γ.

**Administration of DOP Reduced the Insulin Resistance of Obese Mice**

To explore the therapeutic potential of DOP on the IR of obese mice, we treated obese mice with normal saline (NS) or DOP. Notably, mice treated with DOP had lower fasting blood glucose levels and fasting serum insulin (Figures 4A,B). The HOMA-IR index was also lowered in the DOP-treated group (Figure 4C). Moreover, DOP could also suppress VAT inflammation. The levels of pro-inflammatory cytokines IL-6 and TNFα were also decreased, while the anti-inflammatory cytokines IL-10 and IL-4 were increased (Figure 4D). Furthermore, the results of the GTT and ITT revealed that glucose tolerance and clearance in mice were increased after administration of DOP (Figures 4E,F). Together, these findings suggested that administration of DOP reduced IR and adipose tissue inflammation in obese mice.

**DOP Impaired Lipid Metabolism Disorder in Obese Mice**

To further explore the effect of DOP on lipid metabolism in obese mice, serum, and hepatic lipid levels were assayed. DOP-treated mice exhibited significantly lower TG levels in the liver when compared with untreated mice (Figure 5A). In addition, FFA,
serum TC, TG, and LDL-C levels in DOP-treated mice were also lower than in the control group (Figures 5B–E). Importantly, DOP treatment was effective in increasing HDL-C levels (Figure 5F). The H&E staining and Oil Red O staining of the liver samples indicated that compared with the control group, the lipid levels and volumes were decreased in DOP treatment group in ob/ob mice (Figure 5G). Taken together, these results showed that DOP could ameliorate lipid metabolism disorders in obese mice.

DOP Treatment Alleviated Insulin Resistance in Ob/Ob Mice
To further confirm the therapeutic effect of DOP, ob/ob mice were orally administered DOP as mentioned above. Similar to the observations in obese mice, ob/ob mice treated with DOP also exhibited decreased fasting blood glucose levels, fasting serum insulins, and a lower HOMA-IR index (Figures 6A–C). In addition, VAT inflammation was also restrained by DOP treatments exhibited by reduced levels of inflammatory cytokines (IL-6 and TNFα) and elevated expression of anti-inflammatory cytokines (IL-10 and IL-4) (Figure 6D). The results from the GTT and ITT indicated that the application of DOP could improve the glucose intolerance of ob/ob mice (Figures 6E,F). Thus, all these results indicated that DOP treatment could alleviate IR and adipose tissue inflammation in ob/ob mice.

DISCUSSION
Obesity is the basis of IR, which is a potential cause of a complex metabolic syndrome, including hypertension, elevated fasting blood glucose, low HDLC, and elevated TG levels (Beale, 2013). Therefore, there is an urgent need to identify potential therapeutic agents and suitable targets to attenuate IR and abnormal lipid metabolism in obese patients. In this study, we confirmed the potential therapeutic target of PPAR-γ in obese mice and the role of DOP in attenuating IR and abnormal lipid metabolism.

IR is defined as the decreased sensitivity to insulin and response of insulin to target organs and tissues (liver, adipose tissue, skeletal muscle) (Samuel and Shulman, 2012). IR can lead to an increase in intracellular glucose concentration and a decrease in glucose uptake. However, for the liver, IR is characterized by an inability to inhibit liver glucose production and glycogen decomposition (Randle et al., 1963; Randle et al., 1964; Randle et al., 1965). AKT protein kinase in adipocytes,
muscle cells, and liver cells is the key kinase regulating glucose homeostasis (Czech, 2017). Previous studies have found that fatty acid stimulation is an early event of IR (Lee et al., 2014). In this study, we used PA to treat adipocytes, myocytes, and hepatocytes to establish IR models of the three cell types. We then measured glucose uptake or output and insulin-stimulated AKT phosphorylation in these insulin-resistant cells with or without DOP treatment. As expected, DOP treatment significantly promoted the insulin-stimulated glucose uptake of 3T3-L1 adipocytes and C2C12 myocytes, while the glucose output from hepatocytes decreased. Therefore, it is likely that DOP is an agent for potential treatment or prevention of IR.

Multiple mechanisms are involved in the IR of type 2 diabetes. PPAR-γ is a subfamily of nuclear receptors. Activation of PPAR-γ has been reported to improve blood glucose control and systemic insulin sensitivity in patients with type 2 diabetes (Semple et al., 2006). The activation of nuclear receptor PPAR-γ in adipose tissue, liver, and muscle is a determinants of insulin sensitivity (Lu et al., 2011; Germoush et al., 2019). In accordance with previous studies, our results showed that DOP could up-regulate the expression of PPAR-γ in adipocytes, myocytes, and hepatocytes.

IR can lead to hyperinsulinemia and impaired fasting blood glucose (elevated fasting blood glucose). Further, ITT, and GTT are also effective methods to evaluate IR (Guerre-Millo et al., 2001). IR can be diagnosed clinically by a homeostasis model of IR (HOMA-IR) based on fasting blood glucose and fasting serum insulin levels (Yee et al., 2019). To further explore the therapeutic effects of DOP on IR, we conducted in vivo experiments using and obese IR mouse model. The results showed that the levels of fasting blood glucose and fasting serum insulin in the DOP-treated group were significantly lower than those in the control group. Through the ITT and GTT, we found that the blood glucose concentration of mice treated with DOP decreased significantly, which indicated that DOP treatment could significantly increase the glucose tolerance of obese mice and clearance rate of insulin to blood glucose. Furthermore, an increase in obesity-induced lipid storage leads to adipose tissue dysfunction and promotes adipocyte secretion of pro-inflammatory cytokines, including TNF-α and IL-6. Moreover, due to the transformation of M2 macrophages to M1 in obesity tissues, the expression of anti-inflammatory cytokines IL-10 and IL-4 secreted by M2 macrophages is decreased (Taylor, 2021). Changes in the expression of these markers lead to VAT inflammation, which in turn promotes IR. However, our study showed that DOP treatment can reverse the changes in pro-inflammatory and anti-inflammatory cytokines caused by obesity. These results once again confirmed the therapeutic effects of DOP on obesity-induced IR.

Typical obesity-induced dyslipidemia includes elevation in TC, TG, and FFA levels; normal or mildly elevated LDL-C; and decreased HDL-C levels (Klop et al., 2013). Multiple studies have shown that these changes in lipid metabolism are closely related to IR (Reaven et al., 1988; Frayn, 1993; Boden et al., 1994; Ormazabal et al., 2018). Therefore, we analyzed the levels of serum and liver lipids in obese mice with or without DOP treatment. The FFA and serum TC, TG, and LDL-C levels were lower and the serum HDL-C levels were higher in DOP-treated mice than control mice. These results were similar to the study by Yang et al. study, whereby DOP treatment reduced the
metabolic disorder of liver lipids (fatty acids, TG, and glycerolipids) and reduced the symptoms of lipid accumulation in the liver of type 2 diabetic rats (Yang et al., 2020). Thus, we believe that DOP treatment can improve disorders of obesity-induced lipid metabolism.

Interestingly, only a handful of studies have been published in areas related to DOP and obesity to date. The present study investigated whether DOP could improve IR and lipid metabolism disorders in DIO mice. In order to better demonstrate the therapeutic effects of DOP, we used the ob/ob mouse, a genetic model of obesity. Leptin-deficient (ob/ob) mice are an excellent model of obesity and IR (Tomita et al., 1992) and are characterized by elevated insulin and glucose levels and by elevated plasma TG and TC, dyslipidemia, and IR (Dubuc, 1976; Fellmann et al., 2013). Concordant with DIO mice, DOP treatment significantly improved glucose tolerance and insulin clearance of blood glucose in ob/ob mice. Remarkably, DOP has also been shown to inhibit VAT inflammation and liver lipid deposition in the ob/ob mouse model of hereditary obesity. Further, this model was used to further confirm the therapeutic effects of DOP on obesity-related IR and lipid metabolism disorders.

There is a limitation to be noted in our study. Hyperinsulinemic-euglycemic clamp studies are the “gold standard” for evaluating IR, but in our study, we did not adopt this method due to the limitations of the experimental conditions. Nonetheless, an important strength of our study is that it is the first to confirm that DOP can reduce IR and improve abnormal lipid metabolism in obese mice.

In conclusion, DOP can improve insulin sensitivity by upregulating the expression of PPAR-γ, thus improving obesity-related IR. In addition, DOP can treat disorders of lipid metabolism in obese mice. To our knowledge, our study is the first to confirm that DOP can reduce IR and improve abnormal lipid metabolism in obese mice, which provides a novel therapeutic option for the treatment of obesity-related IR and lipid metabolism disorders.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.
ETHICS STATEMENT

The animal study was reviewed and approved by the Institutional Animal Care and Use Committee of the Laboratory Animal Research Center at Xiangya Medical School of Central South University, China.

AUTHOR CONTRIBUTIONS

Study design: QL, SH; Study conduct: XX, WW, HZ, HL, and JW; Data collection: XX, WW, ZZ, HL, HZ, and JW; Data analysis: QL, XX, XL, and JQ; Data interpretation: QL, XX, XL, and JQ; Drafting manuscript: XX and WW; Revising manuscript content: QL, XX, ST; Approval of the final manuscript: QL, XX, WW, HZ, HL, XL, JW, ZZ, and SH are responsible for the integrity of the data analysis, and all authors take responsibility for and attest to the integrity of the data analysis. QL and SH are responsible for sharing the editors’ comments with the other authors.

FUNDING

This work was supported by the Natural Science Foundation of Hunan Province (2020J4799) and National Science and Technology Major Project (Grant No:2020ZX09201-28).

REFERENCES

Barazzoni, R., Gortan Cappellari, G., Ragni, M., and Nisoli, E. (2018). Insulin Resistance in Obesity: an Overview of Fundamental Alterations. *Eat. Weight Disord.* 23 (2), 149–157. doi:10.1007/s40519-018-0481-6

Beale, E. G. (2013). Insulin Signaling and Insulin Resistance. *J. Investig. Med.* 61 (1), 11–14. doi:10.2310/JIM.0b013e3182746f95

Belkina, A. C., and Denis, G. V. (2010). Obesity Genes and Insulin Resistance. *Curr. Opin. Endocrinol. Diabetes Obes.* 17 (5), 472–477. doi:10.1097/MED.0b013e32833c5c48

Boden, G., Chen, X., Ruiz, J., White, J. V., and Rossetti, L. (1994). Mechanisms of Fatty Acid-Induced Inhibition of Glucose Uptake. *J. Clin. Invest.* 93 (6), 2438–2446. doi:10.1172/JCI17252

Council of the Obesity, S. (2008). Obesity as a Disease: the Obesity Society Council Resolution. *Obesity (Silver Spring)* 16 (6), 1151. doi:10.1038/oby.2008.246

Crowe, S., Wu, L. E., Economou, C., Turpin, S. M., Matzaris, M., Hoehn, K. L., et al. (2009). Pigment Epithelium-Derived Factor Contributes to Insulin Resistance in Obesity. *Cel Metab.* 10 (1), 40–47. doi:10.1016/j.cmet.2009.06.001

Czech, M. P. (2017). Insulin Action and Resistance in Obesity and Type 2 Diabetes. *Nat. Med.* 23 (7), 804–814. doi:10.1038/nmm.4350

De Lorenzo, A., Gratteri, S., Guaitieri, P., Cammarano, A., Bertucci, P., and Di Renzo, L. (2019). Why Primary Obesity Is a Disease?. *J. Transl Med.* 17 (1), 169. doi:10.1186/s12967-019-1919-y

Dubuc, P. U. (1976). The Development of Obesity, Hyperinsulinemia, and Hyperglycemia in Ob/ob Mice. *Metabolism.* 25 (12), 1567–1574. doi:10.1016/0026-0495(76)90109-8

Esposito, K., Ponzillo, A., Giugliano, F., Giugliano, G., Marfella, R., Nicoletti, G., et al. (2003). Association of Low Interleukin-10 Levels with the Metabolic Syndrome in Obese Women. *J. Clin. Endocrinol. Metab.* 88 (3), 1055–1058. doi:10.1210/jc.2002-021437
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., et al. (2003). Chronic Inflammation in Fat Plays a Crucial Role in the Development of Obesity-Related Insulin Resistance. *J. Clin. Invest.* 112 (12), 1821–1830. doi:10.1172/JCI19451

Yang, J., Chen, H., Nie, Q., Huang, X., and Nie, S. (2020). Dendrobium Officinale Polysaccharide Ameliorates the Liver Metabolism Disorders of Type II Diabetic Rats. *Int. J. Biol. Macromolecules*. 164, 1939–1948. doi:10.1016/j.ijbiomac.2020.08.007

Yee, H. Y., Yang, J. J., Wan, Y. G., Chong, F. L., Wu, W., Long, Y., et al. (2019). Molecular Mechanisms of Insulin Resistance and Interventional Effects of Chinese Herbal Medicine. *Zhongguo Zhong Yao Za Zhi*. 44 (7), 1289–1294. doi:10.19540/j.cnki.cjcmm.20181105.003

Ying, W., Riopel, M., Bandyopadhyay, G., Dong, Y., Birmingham, A., Seo, J. B., et al. (2017). Adipose Tissue Macrophage-Derived Exosomal miRNAs Can Modulate In Vivo and In Vitro Insulin Sensitivity. *Cell*. 171 (2), 372–384 e312. doi:10.1016/j.cell.2017.08.035

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Qu, Tan, Xie, Wu, Zhu, Li, Liao, Wang, Zhou, Huang and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.